Investigational drug · Phase 2
Tuspetinib
Also called: HM43239
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Tuspetinib"
First trial start
2019
Mar 11, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tuspetinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Myeloid, Acute
- Refractory AML
- Relapsed Adult AML
- Myelodysplastic Syndrome With Excess Blasts-2
- Chronic Myelomonocytic Leukemia
Approved drugs for the same conditions: Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Tuspetinib" as an intervention, largest first.
Aptose Biosciences Inc.Industry
NCT03850574 · 240 participants (planned) · Start Mar 11, 2019 · Primary completion Nov 2026
Drug: Tuspetinib; Venetoclax Oral Tablet and 1 more · For: Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML and 2 more
Sites: Birmingham, Alabama; Duarte, California; Irvine, California · 34 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Tuspetinib enhances the activity of polymyxin B by inhibiting the GlcNAc6P deacetylase.
Ouyang Y, Zhang J, Cui R, et al. · J Antibiot (Tokyo) 2026
- A Phage-Based Approach to Identify Antivirulence Inhibitors of Bacterial Type IV Pili.
Shimozono TM, Vogelaar NJ, O'Hara MT, et al. · Microb Biotechnol 2025
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun 2025
- Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3.
Wang Z, An Y, Wang J, et al. · J Biomol Struct Dyn 2024
Also in development for Leukemia, Myeloid, Acute
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- CusatuzumabOV-1001, JNJ-74494550Phase 22 trials
OncoVerity, Inc. · Leukemia, Myeloid, Acute
- AG-120Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- AG-221Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- BG1805Phase 21 trial
Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.